Finance

Company reports loss from operations was $39.6M

Published in Hepatitis Weekly, December 9th, 2002

Isis Pharmaceuticals, Inc., (ISIS), announced financial results for the 3-month and 9-month periods ended September 30, 2002, which includes a strong cash position of $292 million, including short-term investments.

The company's loss from operations was $39.6 million for the first 9 months of 2002, essentially the same as the loss from operations reported for the identical period in 2001.

Revenue for the 3 and 9 months ended September 30, 2002,totaled $20.3 million and $58.3 million, respectively, compared with $19.3 million and $31.5 million, respectively, for the same periods in 2001. The 85% increase in revenue year to date was primarily related...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-12-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry